IN2012MN02623A - - Google Patents
Download PDFInfo
- Publication number
- IN2012MN02623A IN2012MN02623A IN2623MUN2012A IN2012MN02623A IN 2012MN02623 A IN2012MN02623 A IN 2012MN02623A IN 2623MUN2012 A IN2623MUN2012 A IN 2623MUN2012A IN 2012MN02623 A IN2012MN02623 A IN 2012MN02623A
- Authority
- IN
- India
- Prior art keywords
- iii
- levocarrimycin
- content
- isovalerylspiramycin
- pharmaceutical compositions
- Prior art date
Links
- GIDHDUYAXIVIMN-JJORJHTQSA-N CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC Chemical compound CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC GIDHDUYAXIVIMN-JJORJHTQSA-N 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- VCZCNQGYDMIUGX-FLROPGNWSA-N [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7 Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@@H](O[C@H]2[C@@H]([C@H]([C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@](C)(O)C3)[C@@H](C)O2)N(C)C)O)[C@@H](CC=O)C[C@H]1C)OC)OC(=O)CC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 VCZCNQGYDMIUGX-FLROPGNWSA-N 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
- C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010182027 | 2010-05-25 | ||
| PCT/CN2011/074658 WO2011147316A1 (zh) | 2010-05-25 | 2011-05-25 | 左旋可利霉素、其药物组合物、制备方法及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012MN02623A true IN2012MN02623A (https=) | 2015-06-12 |
Family
ID=44975203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2623MUN2012 IN2012MN02623A (https=) | 2010-05-25 | 2011-05-25 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9089586B2 (https=) |
| EP (1) | EP2578596B1 (https=) |
| JP (1) | JP5866737B2 (https=) |
| KR (2) | KR101706519B1 (https=) |
| CN (1) | CN102247396B (https=) |
| BR (1) | BR112012029905B1 (https=) |
| CA (1) | CA2800019C (https=) |
| DK (1) | DK2578596T3 (https=) |
| ES (1) | ES2633737T3 (https=) |
| IN (1) | IN2012MN02623A (https=) |
| MX (1) | MX346873B (https=) |
| MY (1) | MY164230A (https=) |
| PH (1) | PH12012502329A1 (https=) |
| PL (1) | PL2578596T3 (https=) |
| RU (1) | RU2593499C2 (https=) |
| WO (1) | WO2011147316A1 (https=) |
| ZA (1) | ZA201209739B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2578595B1 (en) * | 2010-05-25 | 2017-04-19 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Crystalline levoisovalerylspiramycin i |
| US9945611B2 (en) | 2010-08-04 | 2018-04-17 | Ima Life North America Inc. | Bulk freeze drying using spray freezing and agitated drying |
| ES2649045T3 (es) * | 2010-08-04 | 2018-01-09 | Ima Life North America Inc. | Liofilización a granel mediante congelación por pulverización y secado agitado |
| CN103694295B (zh) * | 2014-01-08 | 2016-01-20 | 华东理工大学 | 一种优化可利霉素组分的方法 |
| CN105497053B (zh) * | 2015-12-31 | 2018-02-13 | 沈阳福洋医药科技有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
| RU2746047C1 (ru) * | 2017-04-06 | 2021-04-06 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Применение карримицина и его фармацевтически приемлемой соли для производства медикаментов для лечения и/или профилактики опухоли |
| RU2766176C2 (ru) * | 2017-07-04 | 2022-02-08 | Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. | Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата |
| CN110051845A (zh) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | 一种mTOR抑制剂、药物组合物及其应用 |
| MX2020007627A (es) * | 2018-01-19 | 2020-11-24 | Shenyang Fuyang Pharmaceutical Tech Co Ltd | Uso de la carrimicina o de sus ingredientes activos. |
| KR20200144568A (ko) * | 2018-04-17 | 2020-12-29 | 상하이 통리엔 파마슈티컬 컴퍼니 리미티드 | 통증 및/또는 발열을 예방 및/또는 치료하는 의약품, 조합 산물 및 그 응용 |
| CN110384802B (zh) * | 2018-04-17 | 2021-09-17 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗发热的药物、组合产品及其应用 |
| CN110384710B (zh) * | 2018-04-17 | 2023-01-10 | 沈阳福洋医药科技有限公司 | 一种用于预防和/或治疗疼痛的药物、组合产品及其应用 |
| CN108992416A (zh) * | 2018-09-27 | 2018-12-14 | 上海同联制药有限公司 | 一种可利霉素肠溶片及其制备方法 |
| KR20220008895A (ko) * | 2019-05-16 | 2022-01-21 | 쉔양 푸양 파마슈티컬 테크놀로지 컴퍼니 리미티드 | 섬유증을 예방, 완화 및/또는 치료하는 약물, 복합 제품 및 이의 응용 |
| CN112239483B (zh) * | 2019-07-18 | 2023-10-27 | 沈阳福洋医药科技有限公司 | 一种化合物及药物组合物 |
| CN111450066B (zh) * | 2020-04-24 | 2022-06-21 | 沈阳信达泰康医药科技有限公司 | 一种可利霉素冻干粉针制剂及其制备方法 |
| WO2021219112A1 (zh) * | 2020-04-30 | 2021-11-04 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5334788A (en) * | 1976-09-11 | 1978-03-31 | Sanraku Inc | Antibiotics spiramycin derivatives |
| CN1169947C (zh) * | 2002-11-19 | 2004-10-06 | 中国医学科学院医药生物技术研究所 | 必特螺旋霉素的基因工程菌株螺旋霉素链霉菌wsj-195 |
| CN1237976C (zh) * | 2003-12-23 | 2006-01-25 | 沈阳同联集团有限公司 | 必特螺旋霉素及其在抗感染性疾病中的应用 |
| RU2007108544A (ru) * | 2004-08-12 | 2008-09-20 | Глаксосмитклайн Истраживацки Центар Загреб Д.О.О.(Hr) | Применение клеточно-специфических конъюгатов для лечения воспалительных заболеваний желудочно-кишечного тракта |
| KR100662363B1 (ko) * | 2004-10-19 | 2007-01-02 | 엘지전자 주식회사 | 디스플레이 기기의 인스톨 장치 및 방법 |
| CN101054553A (zh) * | 2007-04-09 | 2007-10-17 | 中国医学科学院医药生物技术研究所 | 异戊酰螺旋霉素i基因工程菌株的构建 |
| CN101649325B (zh) * | 2009-07-03 | 2011-09-07 | 中国医学科学院医药生物技术研究所 | 一种提高基因工程异戊酰螺旋霉素主组分含量的基因串连技术 |
| EP2578595B1 (en) * | 2010-05-25 | 2017-04-19 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Crystalline levoisovalerylspiramycin i |
-
2011
- 2011-05-25 CA CA2800019A patent/CA2800019C/en active Active
- 2011-05-25 RU RU2012156419/04A patent/RU2593499C2/ru active IP Right Revival
- 2011-05-25 KR KR1020167002375A patent/KR101706519B1/ko active Active
- 2011-05-25 US US13/699,358 patent/US9089586B2/en active Active
- 2011-05-25 PL PL11786088T patent/PL2578596T3/pl unknown
- 2011-05-25 WO PCT/CN2011/074658 patent/WO2011147316A1/zh not_active Ceased
- 2011-05-25 EP EP11786088.2A patent/EP2578596B1/en active Active
- 2011-05-25 MY MYPI2012700968A patent/MY164230A/en unknown
- 2011-05-25 JP JP2013511525A patent/JP5866737B2/ja active Active
- 2011-05-25 KR KR1020127033722A patent/KR101625262B1/ko active Active
- 2011-05-25 PH PH1/2012/502329A patent/PH12012502329A1/en unknown
- 2011-05-25 ES ES11786088.2T patent/ES2633737T3/es active Active
- 2011-05-25 CN CN201110136228.XA patent/CN102247396B/zh active Active
- 2011-05-25 DK DK11786088.2T patent/DK2578596T3/en active
- 2011-05-25 BR BR112012029905-0A patent/BR112012029905B1/pt not_active IP Right Cessation
- 2011-05-25 IN IN2623MUN2012 patent/IN2012MN02623A/en unknown
- 2011-05-25 MX MX2012013469A patent/MX346873B/es active IP Right Grant
-
2012
- 2012-12-21 ZA ZA2012/09739A patent/ZA201209739B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012013469A (es) | 2013-04-03 |
| DK2578596T3 (en) | 2017-07-17 |
| KR20130020906A (ko) | 2013-03-04 |
| EP2578596B1 (en) | 2017-04-19 |
| BR112012029905A2 (pt) | 2019-08-06 |
| US9089586B2 (en) | 2015-07-28 |
| PL2578596T3 (pl) | 2017-09-29 |
| PH12012502329A1 (en) | 2013-02-11 |
| KR20160019970A (ko) | 2016-02-22 |
| EP2578596A4 (en) | 2013-11-06 |
| CA2800019C (en) | 2015-05-26 |
| MX346873B (es) | 2017-03-30 |
| CN102247396B (zh) | 2014-05-28 |
| CN102247396A (zh) | 2011-11-23 |
| ZA201209739B (en) | 2014-03-26 |
| JP5866737B2 (ja) | 2016-02-17 |
| WO2011147316A1 (zh) | 2011-12-01 |
| RU2012156419A (ru) | 2014-06-27 |
| KR101625262B1 (ko) | 2016-05-27 |
| RU2593499C2 (ru) | 2016-08-10 |
| KR101706519B1 (ko) | 2017-02-14 |
| CA2800019A1 (en) | 2011-12-01 |
| US20130150316A1 (en) | 2013-06-13 |
| EP2578596A1 (en) | 2013-04-10 |
| MY164230A (en) | 2017-11-30 |
| ES2633737T3 (es) | 2017-09-25 |
| JP2013528167A (ja) | 2013-07-08 |
| BR112012029905B1 (pt) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012MN02623A (https=) | ||
| JO2944B1 (en) | Long-acting formulations of insulin | |
| MY188960A (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof | |
| BR112013005679A2 (pt) | imidazopiridazinas substituídas | |
| NZ622566A (en) | Chromobacterium bioactive compositions and metabolites | |
| PH12013502685A1 (en) | Algal lipid compositions and methods of preparing and utilizing the same | |
| EP2941263A4 (en) | FROM PSEUDOLYSIMACHION ROTUNDUM VAR. ISOLATED CLEANED EXTRACT SUBINTEGRUM HIGH INGREDIENT, PREPARATION AND COMPOSITION THEREOF AS AN ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF INFLAMMATION, ALLERGIES AND ASTHMA | |
| NZ734152A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| WO2012027727A3 (en) | Lipomacrocycles and uses thereof | |
| BR112012029913A8 (pt) | levoisovalerilespiramicina i, ii ou iii, preparações, métodos de preparação e usos dos mesmos | |
| BR112015012904A2 (pt) | composições e métodos de uso | |
| BR112014018888A8 (pt) | Composição e combinação de fotoestabilizadores e filtros solares bmdbm | |
| PH12013502054A1 (en) | Suspension type topical formulations comprising cyclic depsipeptide | |
| CA2805805C (en) | Bendamustine anionic-catioinic cyclopolysaccharide compositions | |
| WO2012151279A3 (en) | Induction of il-12 using immunotherapy | |
| TR201009167A2 (tr) | Sefalosporin içeren farmasötik granüller. | |
| AU2012207301A8 (en) | Apolipoprotein AIV as an antidiabetic peptide | |
| MX356373B (es) | Composiciones que comprenden un agente antibacterial y tazobactam. | |
| MX2011006567A (es) | Formulaciones de fenilefrina con estabilidad mejorada. | |
| BR112015012986A2 (pt) | composições e métodos de uso | |
| CA2836488C (en) | Methods for treating obesity and/or metabolic syndrome | |
| PH12012502253A1 (en) | Oral care compositions and methods | |
| WO2014054975A3 (ru) | Фармацевтический состав, обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) | |
| WO2014011077A3 (ru) | Фармацевтический состав, обладающий метаболическим, противокатарактным, ретинопротекторным действием (варианты) | |
| BR112014015193A2 (pt) | composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico |